Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.44 |
| ▸ | SCN10A | Q9Y5Y9 | 17/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.35 |
| ▸ | SLC2A4 | P14672 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24906383 | 0.96 | SCN10A (0.43) | AKR1C3AKR1C2SCN10A | |
| SCHEMBL24757830 | 0.94 | SCN10A (0.40) | AKR1C3AKR1C2SCN10ANR3C1SLC2A1 | |
| SCHEMBL24757818 | 0.93 | SCN10A (0.44) | AKR1C3AKR1C2SCN10A | |
| SCHEMBL24906348 | 0.93 | SCN10A (0.40) | AKR1C3AKR1C2SCN10ASLC2A1SLC2A3 | |
| SCHEMBL24758948 | 0.92 | SCN10A (0.42) | AKR1C3AKR1C2SCN10A | |
| SCHEMBL24758207 | 0.91 | SCN10A (0.39) | AKR1C3AKR1C2SCN10A | |
| SCHEMBL24906472 | 0.90 | SCN10A (0.43) | AKR1C3AKR1C2SCN10A | |
| SCHEMBL24906304 | 0.90 | SCN10A (0.43) | AKR1C3AKR1C2SCN10A | |
| SCHEMBL24906316 | 0.90 | SCN10A (0.43) | AKR1C3AKR1C2SCN10A | |
| SCHEMBL24906239 | 0.90 | SCN10A (0.41) | AKR1C3AKR1C2SCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4355733-A1 | SUBSTITUTED PYRAZOLE AMIDES | Grünenthal GmbH (DE) | 2024-04-24 | — | — | EP | claimed |
| WO-2022263498-A1 | SUBSTITUTED PYRAZOLE AMIDES | Grünenthal GmbH (DE) | 2022-12-22 | — | — | WO | claimed |
| EP-4355733-A1 | SUBSTITUTED PYRAZOLE AMIDES | Grünenthal GmbH (DE) | 2024-04-24 | — | — | EP | disclosed |
| US-20230025025-A1 | SUBSTITUTED PYRAZOLE AMIDES | GRUENENTHAL GMBH (DE) | 2023-01-26 | — | — | US | disclosed |
| WO-2022263498-A1 | SUBSTITUTED PYRAZOLE AMIDES | Grünenthal GmbH (DE) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022263498-A1 | SUBSTITUTED PYRAZOLE AMIDES | Grünenthal GmbH (DE) | 2022-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025025-A1 | SUBSTITUTED PYRAZOLE AMIDES | SCN8A, SCN1A, SCN7A | AKR1C3 1950/4885AKR1C2 1995/4885SCN10A 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.